Genmab Soars as Cancer Drug Impresses in a Late-Stage Trial

Genmab A/S shares surged the most in more than six years after its experimental ovarian cancer treatment exceeded analyst expectations in a late-stage trial, boosting confidence in the Danish drugmaker's pipeline. The positive data could pave the way for regulatory submissions and strengthen Genmab's position in the oncology market.